CR9427A - THERAPEUTIC COMBINATION IN CASES OF BENIGN PROSTATIC HYPERPLASIA - Google Patents

THERAPEUTIC COMBINATION IN CASES OF BENIGN PROSTATIC HYPERPLASIA

Info

Publication number
CR9427A
CR9427A CR9427A CR9427A CR9427A CR 9427 A CR9427 A CR 9427A CR 9427 A CR9427 A CR 9427A CR 9427 A CR9427 A CR 9427A CR 9427 A CR9427 A CR 9427A
Authority
CR
Costa Rica
Prior art keywords
cases
benign prostatic
prostatic hyperplasia
therapeutic combination
treatment
Prior art date
Application number
CR9427A
Other languages
Spanish (es)
Inventor
Helmut Haning
Peter Serno
Erwin Bischoff
Original Assignee
Bayer Healthcares Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcares Ag filed Critical Bayer Healthcares Ag
Publication of CR9427A publication Critical patent/CR9427A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

La presente invencion se refiere a nuevos derivados de fenilaminotiazol, a procedimientos para su preparacion, a su uso para el tratamiento y/o profilaxis de enfermedades asi como a su uso para el tratamiento y/o profilaxis de enfermedades, preferiblemente para el tratamiento y/o prevencion de hipertonia y otras enfermedades cardiovasculares.The present invention relates to new phenylaminothiazole derivatives, procedures for their preparation, their use for the treatment and / or prophylaxis of diseases as well as their use for the treatment and / or prophylaxis of diseases, preferably for the treatment and / or prevention of hypertonia and other cardiovascular diseases.

CR9427A 2005-04-13 2007-10-09 THERAPEUTIC COMBINATION IN CASES OF BENIGN PROSTATIC HYPERPLASIA CR9427A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005016981A DE102005016981A1 (en) 2005-04-13 2005-04-13 Combination therapy for benign prostatic hyperplasia

Publications (1)

Publication Number Publication Date
CR9427A true CR9427A (en) 2007-12-17

Family

ID=36608700

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9427A CR9427A (en) 2005-04-13 2007-10-09 THERAPEUTIC COMBINATION IN CASES OF BENIGN PROSTATIC HYPERPLASIA

Country Status (22)

Country Link
EP (1) EP1888075A1 (en)
JP (1) JP2008535877A (en)
KR (1) KR20080007252A (en)
CN (1) CN101193638A (en)
AR (1) AR053575A1 (en)
AU (1) AU2006233567A1 (en)
BR (1) BRPI0610634A2 (en)
CA (1) CA2605224A1 (en)
CR (1) CR9427A (en)
DE (1) DE102005016981A1 (en)
DO (1) DOP2006000074A (en)
GT (1) GT200600145A (en)
IL (1) IL186604A0 (en)
MA (1) MA29683B1 (en)
MX (1) MX2007012567A (en)
PE (1) PE20061338A1 (en)
RU (1) RU2007141518A (en)
SV (1) SV2008002477A (en)
TN (1) TNSN07385A1 (en)
TW (1) TW200716122A (en)
UY (1) UY29473A1 (en)
WO (1) WO2006108519A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US20070093493A1 (en) * 2005-10-12 2007-04-26 Lilly Icos Llc Treatment of benign prostatic hypertrophy and lower urinary tract symptoms
EP1968705A1 (en) * 2005-12-21 2008-09-17 Pfizer Products Incorporated Pharmaceutical combination of a pde-5 inhibitor and a 5-alpha reductase inhibitor
WO2008005039A1 (en) * 2006-07-07 2008-01-10 Teva Pharmaceutical Industries Ltd. Solid compositions comprising tadalafil and at least one carrier
DE102007028869A1 (en) 2007-06-22 2008-12-24 Ratiopharm Gmbh A process for the preparation of a medicament containing tadalafil
AU2008334932B2 (en) 2007-12-13 2014-05-22 Vanda Pharmaceuticals Inc. Method and composition for treating an alpha adrenoceptor-mediated condition
WO2009076664A1 (en) 2007-12-13 2009-06-18 Vanda Pharmaceuticals Inc. Method and composition for treating a serotonin receptor-mediated condition
US8737368B2 (en) 2010-04-26 2014-05-27 Intel Corporation Method, apparatus and system for switching traffic streams among multiple frequency bands
WO2013123965A1 (en) * 2012-02-20 2013-08-29 Synthon Bv A fixed dose pharmaceutical formulation
CN102727456B (en) * 2012-07-03 2016-06-22 北京科信必成医药科技发展有限公司 Drug port cavity disintegrating tablet and preparation method thereof
AU2014299447B2 (en) * 2013-06-28 2019-01-17 Hanmi Pharm. Co., Ltd. Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin
JP2016525548A (en) 2013-07-23 2016-08-25 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉ� Methods and compositions comprising desmopressin in combination with Β-3 adrenergic receptor stimulants
KR20150056443A (en) * 2013-11-15 2015-05-26 한미약품 주식회사 Composite formulation comprising tadalafil and amlodipine
MY181172A (en) * 2014-06-30 2020-12-21 Hanmi Pharm Ind Co Ltd Composite preparation comprising active ingredient-containing film coating layer
ES2781110T3 (en) * 2014-06-30 2020-08-28 Hanmi Pharm Ind Co Ltd Composite material preparation comprising a film coating layer, containing a 5-alpha-reductase inhibitor, and method for the production of the composite material preparation
WO2016003181A1 (en) * 2014-06-30 2016-01-07 한미약품 주식회사 Composite preparation comprising active ingredient-containing film coating layer
WO2016081772A1 (en) * 2014-11-20 2016-05-26 Allergan, Inc. Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist
US20190125685A1 (en) * 2016-03-31 2019-05-02 Hanmi Pharm. Co., Ltd. Composite capsule preparation containing tadalafil and tamsulosin and having improved stability and elution rate
KR101835506B1 (en) * 2016-10-25 2018-03-07 주식회사 에스텍파마 Rapid-acting mixture of tablet containing dutasteride and tadalafil
CN108066347B (en) * 2016-11-16 2021-02-02 深圳万和制药有限公司 Orally disintegrating tablet pharmaceutical composition comprising tamsulosin and dutasteride
KR101879133B1 (en) * 2017-07-11 2018-07-17 (주)동구바이오제약 Agents for preventing or treating urinary disease and preparing the same
TR201715231A2 (en) * 2017-10-09 2019-04-22 Montero Gida Sanayi Ve Ticaret Anonim Sirketi The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base

Also Published As

Publication number Publication date
MA29683B1 (en) 2008-08-01
IL186604A0 (en) 2008-01-20
AR053575A1 (en) 2007-05-09
SV2008002477A (en) 2008-02-08
DE102005016981A1 (en) 2006-10-19
BRPI0610634A2 (en) 2010-07-13
GT200600145A (en) 2007-04-10
WO2006108519A1 (en) 2006-10-19
JP2008535877A (en) 2008-09-04
KR20080007252A (en) 2008-01-17
CA2605224A1 (en) 2006-10-19
RU2007141518A (en) 2009-05-20
AU2006233567A1 (en) 2006-10-19
MX2007012567A (en) 2007-12-10
UY29473A1 (en) 2006-11-30
TNSN07385A1 (en) 2009-03-17
DOP2006000074A (en) 2006-10-15
CN101193638A (en) 2008-06-04
TW200716122A (en) 2007-05-01
PE20061338A1 (en) 2007-01-28
EP1888075A1 (en) 2008-02-20

Similar Documents

Publication Publication Date Title
CR9427A (en) THERAPEUTIC COMBINATION IN CASES OF BENIGN PROSTATIC HYPERPLASIA
ECSP077296A (en) SUBSTITUTED PHENYLAMINOTIAZOLS AND ITS USE
MX2009006704A (en) New compounds.
DOP2006000235A (en) DERIVATIVES OF DICARBOXYL ACIDS AND THEIR USE
CR10305A (en) "SUBSTITUTED DERIVATIVES OF CHROMANOL AND ITS USE.
PA8759601A1 (en) DERIVATIVES OF 2,3-DIHYDROIMIDAZO [1,2-C] SUBSTITUTED QUINAZOLINE USEFUL FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISEASES ASSOCIATED WITH ANGIOGENESIS
CL2007002513A1 (en) COMPOUNDS DERIVED FROM SUBSTITUTED ISOINDOLIN, INTERMEDIATE COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT AND PREVENTION OF DISEASES SUCH AS CANCER, PAIN, MACULAR DEGENERATION, AMONG OTHERS.
HN2006009702A (en) PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT
UY31484A1 (en) HETEROARIL-SUBSTITUTED PIPERIDINS
HN2008001720A (en) ARILIMIDAZOLONAS AND ARILTRIAZOLONAS REPLACED AS INHIBITORS OF VASOPRESINE RECEPTORS
CR11731A (en) COMPOSITIONS AND PROCEDURES FOR PREPARATION AND USE
BRPI0917017B8 (en) s-nitrosoglutathione reductase pyrrole inhibitors as therapeutic agents
GT200500266A (en) NEW DERIVATIVES OF PYRIMIDINE AND ITS USE
MY147247A (en) Organic compounds and their uses
ATE456369T1 (en) FLIBANSERIN FOR THE TREATMENT OF URINARY INCONTINENCE AND ASSOCIATED DISEASES
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
BR122018009866B8 (en) methods for preparing aminocyclohexyl ether compounds and intermediate compounds
UY29416A1 (en) PYRIMIDINCARBOXYL ACID DERIVATIVES AND ITS USE
BRPI1015539A2 (en) burn treatment compositions and methods
BRPI0518448A2 (en) pharmaceutical compositions comprising a camptothecin derivative
UY29417A1 (en) ENDOPARASITICID AGENTS
HN2005030779A (en) NONADEPSIPEPTIDES ACILATED II
CL2008003659A1 (en) Compounds derived from 6- (4-benzylpiperazin-1-yl) pyrimidin-4-one, modulators of the enzyme stearoyl-coa-desaturase 1; preparation procedure; pharmaceutical composition; and use in the treatment and prophylaxis of obesity.
GT200800066A (en) DERIVATIVES OF 9-CHLORINE-15-DEOXIPROSTAGLANDIN, PROCEDURE FOR PREPARATION AND USE AS A MEDICINAL PRODUCT.
HN2003000104A (en) CYCLOPENTENE DERIVATIVES

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)